Product news

GlaxoSmithKline announced the approval of Requip XL(ropinirole extended-release tablets) in the US for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

June 19, 2008

5:24 pm

GlaxoSmithKline announced the approval of Requip XL(ropinirole extended-release tablets) in the US for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. The product should be available in pharmacies in mid-July 2008.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.